C
Overview
Catch Bio provides a digital platform for personalized cancer prevention and screening plans. It analyzes 500+ risk factors to estimate lifetime risk for 21 cancers and offers a tailored plan with lifestyle changes and a screening protocol, while tracking risk with biomarkers and wearables. It differentiates itself by delivering a concrete, personalized plan with continuous risk monitoring through a direct-to-consumer subscription. Its goal is to reduce individual cancer risk by up to 60% and advance prevention and early detection.
Work here?Claim your company
Simplify's take
What believers are saying
- Catch added Apple Health, Whoop, Oura, Fitbit, and Garmin integrations on 2026-10-15.
- Its science page cites 10,000 clinical studies and 21-cancer coverage on 2026-10-27.
- The roadmap now includes heart disease and Alzheimer's risk, widening subscription retention beyond oncology.
What critics are saying
- Catch still lacks public FDA clearance or peer-reviewed clinical outcomes for its 60% claim.
- Secondary databases conflict on funding, listing $750K versus $40.8M, signaling poor transparency.
- A misfire in screening guidance triggers liability, physician rejection, and a brand-ending trust collapse.
What makes Catch Bio unique
- Catch prices personalized cancer screening at $199 yearly, updated on 2026-10-15.
- Its model scores 21 cancers using 500-plus risk factors and 50-plus biomarkers.
- Catch generates doctor letters and annual protocols, not generic age-based screening reminders.
Help us improve and share your feedback! Did you find this helpful?